EarningsQ2 2026 Earnings Report

Alcon (ALCN) Q2 2026 Earnings Report

0 Followers

Previous Report: Q1 2026

MX:ALCN Q2 2026 EPS Results

Actual EPS$15.11

Consensus EPS$13.41

Beat/MissBeat by +$1.71

One Year Ago EPS$13.56

MX:ALCN Q2 2026 Revenue Results

Actual Revenue$49.52B

Expected Revenue$48.82B

Beat/MissBeat by +$700.59M

YoY Revenue Growth+3.95%

Earnings Announcement Details

QuarterQ2 2026

Date08/10/2026

TimeAfter Close

Conference CallMonday, August 10, 2026

MX:ALCN Upcoming Earnings

Alcon's next earnings date is estimated for November 10, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:ALCN Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Aug 10, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed a clearly positive operational and financial quarter: 7% consolidated sales growth, strong equipment performance (UNITY), margin expansion (+250 bps gross margin, +160 bps operating margin), EPS and cash-flow strength, and multiple successful new-product introductions (PanOptix Pro, TRYPTYR, Valeda). Notable negatives included the discontinuation of the PowerVision accommodating IOL program, slower growth in implantables and certain glaucoma products, a few one-time margin items and manufacturability timing for UNITY DX. On balance, the positives — consistent revenue and margin expansion, robust cash generation and multiple high-potential product rollouts and market-share gains — outweigh the setbacks.

Company Guidance

Alcon reiterated its 2026 assumptions and guidance: it expects aggregate eye‑care markets to grow 3%–4%, with FX rates as of end‑July and current tariffs (U.S. import rates ~10%–12.5%) holding through year‑end; constant‑currency sales growth is guided to 5%–7%, with tougher equipment comps in H2 partially offset by easier contact‑lens comps (particularly Q4) and launch contributions from TRYPTYR, Valeda, UNITY CS and PanOptix Pro (Europe). Management forecast core operating margin expansion of 90–190 basis points (constant currency), raised core diluted EPS growth to 12%–15% (constant currency), expects SG&A in H2 to be consistent with last year as a percent of sales while reinvesting roughly two‑thirds of an anticipated ~$60M Q3 tariff refund (≈$40M) back into the business, and noted a Q2 core gross margin of 64.7% (up 250 bps YoY), Q2 core tax rate of 20.7%, interest expense of $53M, and healthy H1 free cash flow of $693M with $538M returned to shareholders.

Top-line Revenue Growth

Total sales of $2.8 billion, up 7% year-over-year (constant currency), broad-based growth across franchises and geographies.

Strong Equipment Performance Driven by UNITY

Equipment sales $279 million, up 25% year-over-year; UNITY VCS/CS adoption robust with ASPs above expectations and clear second-half placement visibility; first sale of UNITY M microscope recorded.

Vision Care and Contact Lens Momentum

Vision Care sales $1.2 billion, up 7%; contact lens sales $726 million, up 5% (U.S. very strong, ~8%); record global market share in contact lenses with notable growth in TOTAL1, PRECISION1 and PRECISION7 (PRECISION7 sales more than doubled vs prior year).

Ocular Health Outperformance

Ocular health sales $486 million, up 12%; TRYPTYR captured ~5% market share less than a year post-launch with market access covering ~2/3 commercial lives and >20% Medicare lives; Systane delivered double-digit growth and multi-dose preservative-free portfolio grew >40%.

PanOptix Pro Adoption and IOL Portfolio Progress

PanOptix family grew double digits; PanOptix Pro adoption exceeded expectations (PanOptix Pro accounts ~90% of PanOptix implants); TruPlus (CE Mark) launched with KOL activity in U.S.; Vivity Pro submitted and expected with KOLs late this year.

Profitability and Earnings Expansion

Core gross margin 64.7%, up 250 basis points year-over-year; core operating income $574 million (20.6% of sales), up 160 basis points on a constant currency basis; core diluted EPS $0.84, up 9% year-over-year.

Strong Cash Generation and Capital Return

Generated $693 million of free cash flow in the first half and returned $538 million to shareholders through dividends and repurchases; share repurchase program contributing to EPS uplift.

Raised 2026 Profitability and EPS Targets

Revised guidance maintains sales growth of 5%–7% (constant currency) and increases expected core operating margin expansion to 90–190 basis points; core diluted EPS growth outlook raised to 12%–15% (constant currency).

Valeda & Pipeline Optionality

Valeda uptake accelerated; clinical data showed >80% of patients maintained or improved vision at ~2 years; management reiterates potential peak sales of $100–$150 million over time; robust IOL and other pipeline initiatives and collaboration with RxSight underway.

AT-IOL Penetration Driving Upside

AT-IOL penetration increased ~110 basis points globally and ~180 basis points in the U.S.; company highlights contribution sensitivity: ~ $10M/quarter per 1 point cataract market growth and ~$15M/quarter per 1 point AT-IOL penetration.

MX:ALCN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 10, 2026	2026 (Q3)	15.82 / -	13.983	―
Aug 10, 2026	2026 (Q2)	13.41 / 15.11	13.561	11.46% (+1.55)
May 05, 2026	2026 (Q1)	14.12 / 14.69	13.605	7.99% (+1.09)
Feb 24, 2026	2025 (Q4)	13.74 / 13.38	14.271	-6.22% (-0.89)
Nov 11, 2025	2025 (Q3)	13.58 / 13.98	15.869	-11.89% (-1.89)
Aug 19, 2025	2025 (Q2)	12.87 / 13.56	14.005	-3.17% (-0.44)
May 13, 2025	2025 (Q1)	14.32 / 13.61	15.692	-13.30% (-2.09)
Feb 26, 2025	2024 (Q4)	14.07 / 14.27	13.672	4.38% (+0.60)
Nov 12, 2024	2024 (Q3)	14.18 / 15.87	12.984	22.22% (+2.89)
Aug 20, 2024	2024 (Q2)	14.40 / 14.00	13.45	4.13% (+0.55)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed